International Journal of Pharmacy and Analytical Research (IJPAR)
IJPAR |Vol.15 | Issue 1 | Jan - Mar -2026
www.ijpar.com
ISSN: 2320-2831
DOI: https://doi.org/10.61096/ijpar.v15.iss2.2026.541-548

Nanoparticles in Drug Delivery System

Dhamodhara Prasad, Fathima sifna

Department of Pharmaceutics RKP College of Pharmacy, Krishnagiri, Tamil Nadu – 635001

Address for Correspondence: Dhamodhara Prasad

Email id: fathimasifna786@gmail.com

Published on:
07.04.2026

Published by:
Futuristic Publications

Abstract

The traditional administration of therapeutic compounds is frequently hindered by poor solubility, rapid systemic clearance, and non-specific biodistribution, leading to suboptimal therapeutic outcomes and significant off-target toxicities. This project explores the transition from conventional dosage forms to Nanoparticulate Drug Delivery Systems (NDDS) as a transformative solution to these pharmacological challenges. By engineering carriers at the 1–1000 nm scale—including Lipid Nanoparticles (LNPs), polymeric nanospheres, and inorganic matrices—it is possible to protect sensitive "cargo" from enzymatic degradation while enhancing the bioavailability of hydrophobic drugs. This study examines the core mechanisms of passive targeting via the Enhanced Permeability and Retention (EPR) effect and active targeting through surface functionalization with specific ligands. Key strategies such as PEGylation are discussed as a means to evade the Mononuclear Phagocyte System (MPS) and extend biological half-life. While challenges regarding long-term nanotoxicity and manufacturing scalability remain, the integration of nanotechnology into drug delivery facilitates a shift toward personalized, stimuli-responsive medicine. Ultimately, this report concludes that nanoparticle-based systems represent a vital milestone in modern pharmaceutics, offering a high-precision platform for treating complex diseases with improved safety and efficacy.

Keywords: Nanoparticles, Drug Delivery Systems, Lipid Nanoparticles, Targeted Therapy, Pharmacokinetics, PEGylation, Bioavailability.

1. INTRODUCTION

The evolution of pharmaceutical science has shifted from conventional dosage forms toward controlled drug delivery systems (DDS) to overcome the inherent limitations of non-specific biodistribution. In conventional therapy, drugs are often absorbed and distributed randomly throughout the body, leading to "off-target" effects where healthy tissues are damaged, resulting in systemic toxicity and decreased efficacy. This challenge is particularly evident with small-molecule medicines that show promise in laboratory settings but fail in human clinical trials due to rapid clearance or poor solubility. Nanotechnology addresses these hurdles by engineering carriers at the atomic or molecular level, typically ranging from 1 to 1000 nm. These nanoparticles (NPs) provide a precise, cost-effective platform for the target-specific delivery of therapeutic agents, ensuring they reach the intended site at a concentration that is effective yet safe.

At the nanoscale, materials exhibit unique physicochemical and biological properties that differ significantly from their bulk counterparts. Because a substantial portion of a nanoparticle's mass is located on its surface, these systems possess an exceptionally high surface-area-to-volume ratio, allowing for high drug-loading capacity and enhanced reactivity. Nanoparticles are complex architectures generally composed of a surface layer, a shell, and a core where the drug is encapsulated or attached. This structure allows for "stealth" modifications, such as PEGylation, which creates a

hydrophilic shield to evade the body's immune system and prolong circulation time. Furthermore, the ability to functionalize the NP surface with specific ligands enables active targeting of diseased cells, significantly reducing the required dosage and minimizing adverse drug reactions.

A prominent illustration of this technology's clinical success is the development of Lipid Nanoparticles (LNPs), which played a vital role in the delivery of mRNA for recent global vaccination efforts. LNPs are spherical vesicles composed of ionizable lipids, phospholipids, cholesterol, and PEG-ylated lipids that mimic cell membranes to facilitate intracellular uptake. By protecting sensitive genetic material or toxic drugs from enzymatic degradation, these systems ensure stable transport through the systemic circulation. As research progresses into stimuli-responsive "smart" nanoparticles, the field is moving toward personalized medicine where treatments are tailored to specific biological markers. Ultimately, nanoparticle-based delivery systems represent a milestone in modern pharmaceutics, transforming the management of complex diseases like cancer and tuberculosis through unmatched precision and safety.

Structural Diversity and Composition

The versatility of nanoparticles lies in their diverse morphology and composition. They are not simple molecules but complex architectures typically composed of three layers: the surface layer, the shell, and the core. Physically, they can manifest in various shapes—spherical, cylindrical, tubular, or irregular—and can be classified by their dimensionality (0D to 3D).

A prominent example of this structural precision is the Lipid Nanoparticle (LNP), which gained global recognition for its role in mRNA delivery for



COVID-19 vaccines. LNPs consist of four critical components:

Ionizable Lipids: Facilitate binding to negatively charged cargo (like nucleic acids) and enable endosomal escape in low-pH environments.

PEG-ylated Lipids: Ensure particle stability andhydrophilicity.

Phospholipids: Support the structural integrity of the bilayer.

Cholesterol: Maintains membrane fluidity and facilitates intracellular uptake.

2. CLASSIFIACTION

2.1. Organic Nanoparticles

These are primarily composed of organic molecules like lipids or polymers and are favored for their high biocompatibility and biodegradability.

Lipid-Based Nanoparticles: This includes Liposomes (phospholipid bilayers) and Lipid Nanoparticles (LNPs). As highlighted in the mRNA vaccine studies, these utilize ionizable lipids and cholesterol to mimic cell membranes for intracellular delivery.

Polymeric Nanoparticles: These are subdivided into Nanocapsules (where the drug is confined to a cavity surrounded by a polymer membrane) and Nanospheres (where the drug is dispersed throughout the polymer matrix). Common materials include PLGA, polycaprolactone, and natural polymers like Chitosan.

Dendrimers: Highly branched, star-shaped macromolecules with a high degree of symmetry. Their surface "branches" can be functionalized with multiple drug molecules or targeting ligands.

2.2. Inorganic Nanoparticles

These utilize non-organic materials, often providing unique optical, magnetic, or electrical properties used in "theranostics" (therapy + diagnostics).

Metal-Based Nanoparticles: Primarily Gold (Au) and Silver (Ag) nanoparticles. Gold NPs are frequently used for photothermal therapy due to their surface plasmon resonance.

Magnetic Nanoparticles: Usually composed of iron oxide (magnetite). These can be guided to a specific body site using an external magnetic field.

Silica Nanoparticles: Mesoporous silica provides a large surface area and stable pore structure for high drug loading.

Carbon-Based Nanoparticles: Includes Carbon Nanotubes (CNTs) and Fullerenes, which are characterized by high mechanical strength and electrical conductivity.



2.3. Classification by Dimensionality

Based on the physical structure and electron movement, nanoparticles are categorized into:

0D (Zero-Dimensional): All dimensions are at the nanoscale (e.g., uniform nanospheres, quantum dots).

1D (One-Dimensional): Two dimensions are at the nanoscale, but one is elongated (e.g., nanotubes, nanorods, nanowires).

2D (Two-Dimensional): Only one dimension is at the nanoscale, resulting in plate-like shapes (e.g., nanofilms, nanocoatings, graphene sheets).

3D (Three-Dimensional): Complex structures that are not confined to the nanoscale in any dimension but are composed of individual nanocrystals or powders.

2.4. Classification by Morphology and Surface Charge

Shape-Based: Spherical, conical, tubular, or irregular. Anisotropic shapes (like prisms) often exhibit different biological uptake rates compared to spheres.

Surface Charge: Anionic (negative), Cationic (positive), or Neutral. Cationic NPs are often used to bind negatively charged genetic material (DNA/RNA) but may have higher systemic toxicity than neutral or PEGylated "stealth" particles.

3. TYPES

3.1. Lipid-Based Nanoparticles (LNPs)

As highlighted in the Jainu Ajit and Alva papers, LNPs are the most clinically advanced type. They are spherical platforms consisting of a lipid bilayer or a solid lipid core.

Liposomes: The first generation of nanocarriers, consisting of an aqueous core surrounded by a phospholipid bilayer. They can carry both hydrophilic drugs (in the core) and hydrophobic drugs (in the bilayer).

Solid Lipid Nanoparticles (SLNs): These use solid lipids (like triglycerides) instead of liquid lipids, offering better controlled-release profiles and increased stability for the drug.

3.2. Polymeric Nanoparticles

These are prepared from natural or synthetic polymers. According to Wilczewska, they are classified into two structural types:

Nanospheres: A matrix system where the drug is physically and uniformly dispersed throughout the polymer.

Nanocapsules: A reservoir system where the drug is confined to a central cavity surrounded by a unique polymer shell.

Dendrimers: These are unique, highly branched, "tree-like" polymers. Their multi-functional surface allows for the attachment of many targeting ligands, making them ideal for complex, multi-drug delivery.

3.3. Inorganic Nanoparticles

These types are frequently discussed in the Yusuf et al. review regarding their unique physicochemical properties:

Gold Nanoparticles (AuNPs): Highly stable and easy to functionalize. They are often used in cancer therapy because they can convert light into heat to destroy tumor cells (photothermal therapy).

Magnetic Nanoparticles: Typically made of iron oxide, these allow for "site-specific" delivery by using an external magnetic field to pull the drugs to a specific area of the body.

Quantum Dots: Tiny semiconductor particles (2-10 nm) used primarily for high-resolution biological imaging and tracking drug movement within cells.

3.4. Carbon-Based Nanoparticles

Carbon Nanotubes (CNTs): Graphene sheets rolled into cylinders. They have a high surface area and can penetrate cell membranes effectively, though their long-term toxicity is still being studied.

Fullerenes: Hollow carbon cages (like C60) that can act as antioxidants or carriers for small-molecule drugs.

3.5. Polymeric Micelles

These are formed from amphiphilic block copolymers that spontaneously self-assemble in water. They have a hydrophobic core (to hide insoluble drugs) and a hydrophilic shell (to stay stable in the bloodstream).



4. MECHANISM

4.1. Targeting Mechanisms

Passive Targeting (The EPR Effect): In cancerous tissues, the blood vessels are often "leaky" with large gaps (fenestrations) between endothelial cells. Nanoparticles are small enough to pass through these gaps and accumulate in the tumor. Because tumors also have poor lymphatic drainage, the NPs stay trapped there—a phenomenon known as the Enhanced Permeability and Retention (EPR) effect.

Active Targeting: This involves "decorating" the surface of the NP with ligands (like antibodies, peptides, or folic acid). These ligands act like a key, binding specifically to receptors that are overexpressed on the surface of diseased cells (the "lock"). This ensures the drug is delivered directly to the target, sparing healthy cells.

4.2. Cellular Internalization (Endocytosis)

Once the nanoparticle reaches the target cell membrane, it must enter the cell. Unlike small molecules that may diffuse through the membrane, NPs are typically internalized through Endocytosis:

Adsorption: The NP attaches to the cell membrane.

Invagination: The cell membrane folds inward, wrapping around the NP to form a vesicle called an endosome.

Endosomal Escape: This is a critical step for Lipid Nanoparticles (LNPs). As the pH inside the endosome drops (becomes more acidic), ionizable lipids in the LNP become positively charged. They interact with the negatively charged endosomal membrane, destabilizing it and releasing the drug into the cytoplasm before it can be destroyed by lysosomes.

4.3. Controlled Drug Release Kinetics

The final step is the controlled release of the drug from the nanoparticle matrix. This can happen through several mechanisms depending on the NP type:

Diffusion: The drug molecules move from the high-concentration core of the NP to the lower-concentration environment of the cell.

Polymer Erosion/Degradation: The nanoparticle shell (like PLGA) slowly breaks down or dissolves, gradually releasing the encapsulated drug over days or weeks.

Swelling: In hydrogel-based NPs, the matrix absorbs water and expands, allowing the drug to "leak" out.

Stimuli-Responsive Release: Some "smart" nanoparticles only release their cargo when triggered by specific external or internal factors, such as:

pH-sensitive: Release occurs in the acidic environment of a tumor or endosome.

Thermo-responsive: Release is triggered by a specific temperature (local hyperthermia).

Enzymatic: Release occurs only when a specific enzyme (common in certain diseases) cleaves the NP shell

5. Advantages And Disadvantages

5.1. Advantages of Nanoparticle-Based Delivery Systems

The primary strength of nanotechnology lies in its ability to transform a drug's pharmacokinetic profile. By encapsulating active pharmaceutical ingredients (APIs), we achieve:

Enhanced Solubility and Bioavailability: Many potent new drugs are poorly water-soluble (BCS Class II and IV). Nanoparticles increase the surface area and can carry hydrophobic drugs in a hydrophilic shell, ensuring they are absorbed effectively.

Reduced Systemic Toxicity: By using active targeting (ligands) and passive targeting (EPR effect), drugs accumulate in diseased tissues rather than healthy organs. This significantly reduces the side effects commonly seen in chemotherapy.

Extended Circulation Time: Through PEGylation, nanoparticles evade the Mononuclear Phagocyte System (MPS). This prevents rapid renal clearance and extends the drug's half-life, allowing for less frequent dosing and improved patient compliance.

Protection of Labile Molecules: Sensitive molecules like mRNA, proteins, and peptides are prone to enzymatic degradation. The nanoparticle acts as a protective shield, ensuring the "cargo" remains intact until it reaches the target cell.

Controlled and Sustained Release: Unlike conventional tablets that cause "peaks and valleys" in blood concentration, NP systems can be engineered to release drugs at a constant rate over days or even weeks.

5.2. Disadvantages and Clinical Challenges

Despite their potential, several hurdles remain in the widespread adoption of these systems:

Nanotoxicity and Immunogenicity: Because of their high surface reactivity, some nanoparticles can trigger unintended immune responses or "cytokine storms." There is also concern about the long-term accumulation of non-biodegradable particles (like some inorganic NPs) in the liver or spleen.

Complexity of Manufacturing: Scaling up production from a laboratory "benchtop" to a pharmaceutical factory is difficult. Maintaining a uniform particle size (polydispersity index) and high drug-loading efficiency during large-scale manufacturing is a significant technical challenge.

High Cost of Production: The materials (like ionizable lipids) and the specialized equipment required for "bottom-up" synthesis make these formulations much more expensive than traditional generics.

Stability Issues: Nanoparticles can be physically unstable; they may aggregate (clump together) or the drug may "leak" out prematurely during storage.

Regulatory Hurdles: Because they behave differently than standard chemicals, regulatory bodies like the FDA/EMA require specialized, rigorous testing for "nanosimilar" products, which can delay market entry.

6. Future Scope Of Drug Delivery

The field of nanotechnology is moving beyond simple "passive" carriers toward "intelligent" systems that can sense and respond to the physiological environment. Key areas of future development include:

Stimuli-Responsive "Smart" Nanoparticles: Future research is heavily focused on NPs that only release their cargo when triggered by specific internal cues (like the low pH of a tumor or specific enzyme concentrations) or external triggers (such as localized heat, ultrasound, or light). This "on-demand" release will further reduce systemic side effects.

Theranostics: This is a burgeoning field that combines Therapy and Diagnostics into a single nanoparticle. For example, a gold or magnetic nanoparticle could be used to image a tumor using an

MRI and then immediately be triggered to release a chemotherapy drug or generate heat to kill the cancer cells.

Personalized Nanomedicine: As genomic testing becomes standard, nanoparticles can be custom-functionalized with ligands that match a specific patient's unique cellular receptors. This ensures that the treatment is tailored to the individual's biological profile, a major goal in modern oncology and rare disease treatment.

Oral Delivery of Biologics: A major "holy grail" in pharmacy is the oral delivery of insulin and other proteins. Future nanoparticulate coatings (like mucoadhesive Chitosan) are being designed to protect these sensitive molecules from stomach acid and help them cross the intestinal barrier, potentially replacing daily injections.

Vaccine Technology beyond COVID-19: The success of Lipid Nanoparticles (LNPs) has opened doors for mRNA vaccines against malaria, HIV, and even "cancer vaccines" that train the immune system to recognize and destroy tumor cells.

7. CONCLUSION

Nanotechnology represents one of the most significant milestones in the history of pharmaceutical science. By addressing the fundamental flaws of conventional drug deliverynamely non-specific distribution, poor solubility, and rapid systemic clearancenanoparticles have provided a platform for safer and more effective therapies.

As a pharmacist, it is clear that while challenges such as long-term nanotoxicity, high manufacturing costs, and regulatory complexity remain, the benefits of site-specific delivery far outweigh the risks. The transition from bulk materials to engineered nanoscale systems allows us to transform highly toxic or unstable compounds into life-saving treatments. As we move toward an era of personalized and stimuli-responsive medicine, nanoparticles will undoubtedly remain the cornerstone of innovative drug delivery, ensuring that the "magic bullet" of pharmacology becomes a clinical reality.

REFERECES

[1] Jainu Ajit. Nanoparticles in Drug Delivery. Premier Science. 2023. Available from: [Source Website].

[2] Wilczewska AZ, Niemirowicz K, Markiewicz KH, Car H. Nanoparticles as drug delivery systems. Pharmacological Reports. 2012; 64(5):1020-1037.

[3] Yusuf A, Almotairy ARZ, Henidi H, Alshehri OY, Aldughaim MS. Nanoparticles as drug delivery systems: a review of the implication of nanoparticles' physicochemical properties on responses in biological systems. Polymers. 2023; 15(7):1596.

[4] Alva SH, Shripathy D, Shabaraya AR. Nanoparticle Drug Delivery System: An Overview. International Journal of Pharmaceutical Sciences and Research. Mangaluru: Srinivas College of Pharmacy; 2023.

[5] Patel T, et al. Nanoparticles in Drug Delivery Systems: Challenges, Innovations, and Surface Modification for Targeted Therapeutics. Journal of Nanomedicine & Nanotechnology. 2024.

[6] Bhatia.S, Natural Polymer Drug Delivery Systems. Switzerland: Springer International Publishing; 2016.

[7] Wim De Jong H, Paul Borm JA .Drug delivery and nanoparticles: Applications & hazards. International Journal of Nanomedicine 2008; 3(2): 133-149. DOI - 10.2147/IJN.S596; PMID: 18686775.

[8] Velavan.P, Karruppusamy.C, Venkatesan.P. Nanoparticles as Drug Delivery Systems. Journal of Pharmaceutical Sciences and Research 2015; 7(12):1118-1122.

[9] Wechsler M.E, Vela Ramirez J.E, and Peppas N.A. Nanoparticles Mediated Drug Delivery for the treatment of Alzheimer's disease: crossing the blood brain barrier. Industrial Engineering and Chemistry Research 2019; 58: 15079-15087. DOI:10.1021/acs.iecr.9b02196; PMID :32982041

[10] Saba Hasan. A Review on Nanoparticles: Their Synthesis and Types. Research Journal of Recent sciences, 2015; 4:1-3.

[11] Rajora A.K, Ravishankar.D, Osborn H.M.I, Greco.F. Impact of the enhanced permeability and retention (EPR) effect and cathepsins levels on the activity of polymer-drug conjugates. Polymers 2014;

[12] Lam Shu J, Wong Edgar HH, Boyer Cyrille, Qiao Greg G. Antimicrobial Polymeric Nanoparticles. Progress in Polymer Science, 2018; 10.1016/j.progpolymsci.2017.07.007. 76:40-64.DOI:

[13] Lee C., MacKay.J, Fréchet, Szoka J.C. Designing dendrimers for biological applications. Nature Biotechnology, 2005; 23:1517–1526. DOI: 10.1038/ nbt1171.

[14] Akbarzadeh. A., Rezaei-Sadabady.R, Davaran, Sang Woo Joo, Nosratollah Zerghami Y, Hanifehpour, Samiei.M, Kouhi.M, classification, Koshki preparation, K.N. and Liposome: applications. Nanoscale Research Letters, 2013; 8: 102. DOI: 10.1186/1556-276X-8-102.

[15] Deependra Singh, Pooja Dubey, Madhulika Pradhan, Manju Rawat Singh. Ceramic nanocarriers: versatile Nano system for protein and peptide delivery. Expert Opinion on Drug Delivery, 2013; 10(2): 241-259. DOI: 10.1517/17425247.2012.745848.

[16] Swartejas, J.J.T.M, Sharma P.K, Kooten, Mei T.G.V, Mahmoudi M, Busscher H.J, Rochford E.T.J. Current Developments in Antimicrobial Surface Coatings for Biomedical Applications. Chemistry, 2015; 22: Current Medicinal 2116–2129. DOI: 10.2174/0929867321666140916121355.PMID 25245508.

[17] National Cancer Institute- Benefits of Nanotechnology for Cancer. [Internet] [Updated 2017 Aug 8] Available from: https://www.cancer.gov/nano/cancer nanotechnology/benefits.

[18] Farrokhzad O.C, Langer. Impact of Nanotechnology on Drug Delivery. American Chemical Society, 2009; 3(1): 16-20. DOI: 10.1021/nn900002m.

[19] Walker N, Bucher J. A. 21st century paradigm for evaluating the health hazards of nanoscale materials. Toxicological Sciences, 2009; 110(2): 251-254. DOI- 10.11093/toxsci/kfp106.

[20] Begines B, Ortiz T, Pérez-Aranda M, Martínez G, Merinero M, Argüelles-Arias F, et al. Polymeric Nanoparticles for Drug Delivery: Recent Developments and Future Prospects. Nanomater, 2020; 10(1403): 01-38.

[21] Afzal O, Altamimi ASA, Nadeem MS, Alzarea SI, Almalki WH, Tariq A, et al. Nanoparticles in Drug Delivery: From History to Therapeutic Applications. Nanomater, 2022; 12(4494): 01-27.

[22] Khan I, Saeed K, Khan I. Nanoparticles: Properties, applications and toxicities. Arab J Chem., 2019; 12: 908–31.

[23] Ealias AM, Saravanakumar MP. A review on the classification, characterisation, synthesis of nanoparticles and their application. IOP Conf Ser: Mater Sci Eng., 2017; 263(3): 01-15.

[24] Nikam AP, Ratnaparkhiand MP, Chaudhari SP. Nanoparticles – An Overview. Int J Res Dev Pharm L Sci., 2014; 3(5): 1121-27.

[25] Krishna RN, Gayathri R, Vishnu Priya V. Nanoparticles and Their Applications – A Review. J Pharm Sci & Res., 2017; 9(1): 24-27. 7. Abdellatif AAH, Alsowinea AF. Approved and marketed nanoparticles for disease targeting and applications in COVID-19. Nanotechnol Rev., 2021; 10: 1941–77.

[26] Chenthamara D, Subramaniam S, Ramakrishnan SG, Krishnaswamy S, Essa MM, Lin FH, et al. Therapeutic efficacy of nanoparticles and routes of administration. Biomater Res., 2019; 23(20): 01-29.

[27] Patil N, Bhaskar R, Vyavhare V, Dhadge R, Khaire V, Patil Y. Overview on Methods of Synthesis of Nanoparticles. Int J Curr Pharm Res., 2021; 13(2): 11-16.

[28] Varma MM, Kumar KTS, Srivalli ID. A Review on Nanoparticles: Synthesis, Characterization and Applications. World J Pharm Med Res., 2021; 7(8): 169-79.

[29] Poon C, Patel AA. Organic and inorganic nanoparticle vaccines for prevention of infectious diseases. Nano Express, 2020; 1: 01-11.

[30] Cooper DL, Conder CM, Harirforoosh S. Nanoparticles in drug delivery: mechanism of action, formulation and clinical application towards reduction in drug-associated nephrotoxicity. Expert Opin Drug Deliv, 2014; 11(10): 1661-80.

[31] Ratemi E, Shaik AS, Faraj AA, Halwani R. Alternative approaches for the treatment of airway diseases: focus on nanoparticle medicine. Clin Exp Allergy, 2016; 46: 1033–42.

[32] Heera P, Shanmugam S. Nanoparticle Characterization and Application: An Overview. Int J Curr Microbiol App Sci., 2015; 4(8): 379-86.